Skip to main content
. 2017 Nov 30;8(66):110576–110591. doi: 10.18632/oncotarget.22833

Figure 6. Effects of FR5, LY294002 or combination on Hippo-YAP and PTEN/PI3K/AKT pathways in Bel7402 and HepG2 cells.

Figure 6

Bel7402 and HepG2 cells were treated with FR5 (160 μg/ml) and LY294002 (25μmol/L) used singly or in combination for 24 h, pretreatment of LY294002 was followed by FR5 in combined treatment. (A) Membranes were probed with YAP, phospho-YAP. (B) Membranes were probed with PTEN. (C) Membranes were probed with AKT and phospho-AKT(S473). (D-F) Quantitative analysis of the relative PTEN (E), p-YAP/YAP (D) and p-AKT(S473)/AKT (F) as shown in (A-C). Each bar represented mean±SD of three separate experiments. GAPDH was used as internal control. **p < 0.01 compared with the control group.